Yahoo · Sep 18, 2026
Biotech Options Buzz: UTHR, NMRA, EWTX
UTHR, NMRA, and EWTX are drawing attention from options bears
UT
NYSE · UTHR
United Therapeutics Corporation
Healthcare · Biotechnology
$494.63
Down-$2.64 (-0.53%)
Updated Sep 20, 2026, 12:31 PM
SID Score
6.3/10
Composite research score
Smart Money
58/100
Neutral
- Market cap
- 21.83B
- P/E ratio
- 16.83
- Dividend yield
- 0.00%
- 52-week range
- $408.75 – $609.35
- Volume
- 1.5M
- Avg. volume
- 627.5K
Price performance
UTHR price history
1M range · 19 trading sessions · Daily adjusted prices
UTHR closed at $494.63 after 19 trading sessions, down 3.56% for the selected period.
- Last close
- $494.63
- Period change
- -3.56%
- Period low
- $487.61
- Period high
- $527.91
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 18, 2026 | $498.07 | $499.23 | $492.57 | $494.63 | 1.5M |
| Sep 17, 2026 | $501.49 | $503.325 | $492.59 | $497.27 | 1.45M |
| Sep 16, 2026 | $500.62 | $505.775 | $497.665 | $498.48 | 488.4K |
| Sep 15, 2026 | $505.44 | $507.15 | $498.85 | $500.35 | 1.6M |
| Sep 14, 2026 | $506.78 | $509.065 | $499.62 | $502.70 | 605.73K |
| Sep 11, 2026 | $505.60 | $508.675 | $496.18 | $497.11 | 573.36K |
| Sep 10, 2026 | $502.44 | $509.79 | $497.91 | $503.86 | 653.16K |
| Sep 9, 2026 | $502.75 | $509.525 | $492.90 | $506.82 | 500.11K |
| Sep 8, 2026 | $494.74 | $505.00 | $479.71 | $497.97 | 643.54K |
| Sep 4, 2026 | $484.33 | $494.085 | $484.33 | $487.61 | 327.02K |
| Sep 3, 2026 | $494.09 | $494.09 | $477.06 | $490.24 | 469.58K |
| Sep 2, 2026 | $510.00 | $510.05 | $477.01 | $492.02 | 1.4M |
| Sep 1, 2026 | $514.20 | $517.75 | $510.39 | $512.70 | 479K |
| Aug 31, 2026 | $510.95 | $515.55 | $507.03 | $510.38 | 538.52K |
| Aug 28, 2026 | $527.94 | $530.50 | $513.72 | $515.46 | 266.87K |
| Aug 27, 2026 | $513.98 | $531.76 | $511.00 | $527.91 | 391.01K |
| Aug 26, 2026 | $515.60 | $522.0199 | $513.98 | $516.68 | 254.78K |
| Aug 25, 2026 | $516.07 | $520.655 | $515.54 | $518.53 | 876.5K |
| Aug 24, 2026 | $513.12 | $514.295 | $508.1541 | $512.88 | 323.89K |
Latest UTHR news
The latest Smart Investors Daily articles mentioning UTHR.
Stock researchCompany · Overview
UTHR research
Overview
Company profile and research snapshot.
Company profile
United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. In addition, it is developing a pipeline of projects that includes new indications and delivery devices for existing products and new products to treat PAH and other conditions.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- Buy
- Average target
- $539.83
- Implied upside
- —
- Analysts
- 21
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 6, 2026 | RBC Capital | Outperform | — |
| Jul 23, 2026 | JP Morgan | Overweight | — |
| Jul 10, 2026 | B of A Securities | Neutral | — |
| Jul 7, 2026 | RBC Capital | Outperform | — |
| May 7, 2026 | RBC Capital | Outperform | — |
News briefing
No generated briefing is available yet.
SeekingAlpha · Sep 14, 2026
United Therapeutics Corporation (UTHR) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
United Therapeutics Corporation (UTHR) Morgan Stanley 24th Annual Global Healthcare Conference September 14, 2026 4:50 PM EDTCompany ParticipantsMartine...
Yahoo · Sep 11, 2026
LQDA Loses 13.9% in a Month: Should Investors Avoid the Stock Now?
Liquidia's Yutrepia is gaining traction, but patent litigation, competition, rising costs and heavy product dependence cloud LQDA's outlook.
Yahoo · Sep 11, 2026
Why Is Altimmune (ALT) Up 14.2% Since Last Earnings Report?
Altimmune (ALT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
